Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Sex modifies the APOE-related risk of developing Alzheimer disease.

Altmann A, Tian L, Henderson VW, Greicius MD; Alzheimer's Disease Neuroimaging Initiative Investigators.

Ann Neurol. 2014 Apr;75(4):563-73. doi: 10.1002/ana.24135. Epub 2014 Apr 14.

PMID:
24623176
[PubMed - indexed for MEDLINE]
2.

Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Han MR, Schellenberg GD, Wang LS; Alzheimer's Disease Neuroimaging Initiative.

BMC Neurol. 2010 Oct 8;10:90. doi: 10.1186/1471-2377-10-90.

PMID:
20932310
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A data-driven model of biomarker changes in sporadic Alzheimer's disease.

Young AL, Oxtoby NP, Daga P, Cash DM, Fox NC, Ourselin S, Schott JM, Alexander DC; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2014 Sep;137(Pt 9):2564-77. doi: 10.1093/brain/awu176. Epub 2014 Jul 9.

PMID:
25012224
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.

PMID:
15522251
[PubMed - indexed for MEDLINE]
5.

Injury markers predict time to dementia in subjects with MCI and amyloid pathology.

van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, L'italien G, van der Flier WM, Teunissen CE, Blennow K, Barkhof F, Rueckert D, Wolz R, Verhey F, Visser PJ.

Neurology. 2012 Oct 23;79(17):1809-16. doi: 10.1212/WNL.0b013e3182704056. Epub 2012 Sep 26.

PMID:
23019259
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease.

Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2013;33(3):807-22. doi: 10.3233/JAD-2012-110029.

PMID:
23034521
[PubMed - indexed for MEDLINE]
7.

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.

Mol Psychiatry. 2004 Jul;9(7):705-10.

PMID:
14699432
[PubMed - indexed for MEDLINE]
8.

Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.

J Alzheimers Dis. 2010;21(2):471-8. doi: 10.3233/JAD-2010-091594.

PMID:
20555147
[PubMed - indexed for MEDLINE]
9.

Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.

van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P.

J Alzheimers Dis. 2012;29(2):319-27. doi: 10.3233/JAD-2011-111694.

PMID:
22233766
[PubMed - indexed for MEDLINE]
10.

Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting.

Malnar M, Kosicek M, Bene R, Tarnik IP, Pavelin S, Babic I, Brajenovic-Milic B, Hecimovic H, Titlic M, Trkanjec Z, Demarin I, Hecimovic S.

Acta Neurobiol Exp (Wars). 2012;72(3):264-71.

PMID:
23093013
[PubMed - indexed for MEDLINE]
Free Article
11.

Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.

Alexopoulos P, Guo LH, Kratzer M, Westerteicher C, Kurz A, Perneczky R.

Dement Geriatr Cogn Disord. 2011;32(3):164-70. doi: 10.1159/000332017. Epub 2011 Oct 13.

PMID:
21997402
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.

Alexopoulos P, Guo LH, Jiang M, Bujo H, Grimmer T, Förster S, Drzezga A, Kurz A, Perneczky R.

J Alzheimers Dis. 2013;36(2):401-8. doi: 10.3233/JAD-122329.

PMID:
23609762
[PubMed - indexed for MEDLINE]
13.

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.

Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR Jr, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2014 Jan 4;4:461-72. doi: 10.1016/j.nicl.2013.12.012. eCollection 2014.

PMID:
24634832
[PubMed - in process]
Free PMC Article
14.

Longitudinal changes of CSF biomarkers in Alzheimer's disease.

Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK.

J Alzheimers Dis. 2011;25(4):583-94. doi: 10.3233/JAD-2011-101911.

PMID:
21460434
[PubMed - indexed for MEDLINE]
15.

SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.

Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MM, Williams J, Lovestone S, Peskind ER, Li G, Leverenz JB, Galasko D; Alzheimer's Disease Neuroimaging Initiative, Morris JC, Fagan AM, Holtzman DM, Goate AM.

PLoS Genet. 2010 Sep 16;6(9):e1001101. doi: 10.1371/journal.pgen.1001101.

PMID:
20862329
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.

Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM.

Neurobiol Aging. 2011 Aug;32(8):1372-8. doi: 10.1016/j.neurobiolaging.2009.08.006. Epub 2009 Sep 11.

PMID:
19748159
[PubMed - indexed for MEDLINE]
17.

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA.

Ann Neurol. 2010 Jan;67(1):122-31. doi: 10.1002/ana.21843.

PMID:
20186853
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.

Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, Laitinen M, Remes AM, Koivisto AM, Mattila KM, Lehtimäki T, Verhey FR, Visser PJ, Soininen H, Hiltunen M.

PLoS One. 2013;8(4):e59676. doi: 10.1371/journal.pone.0059676. Epub 2013 Apr 3.

PMID:
23573206
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
[PubMed - indexed for MEDLINE]
20.

Alzheimer disease biomarkers are associated with body mass index.

Vidoni ED, Townley RA, Honea RA, Burns JM; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2011 Nov 22;77(21):1913-20. doi: 10.1212/WNL.0b013e318238eec1.

PMID:
22105948
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk